Why do you need this?
Your individual NPI number is required to verify that you are a health care provider.

 Log In or Register

Log In
 Close
* = Required field


Remember my e-mail address
Log In Forgot Password?
Not Registered?
AZ GatewayAZ Connect
Close
Find My Representative
Find your Personal Account Specialist, who can answer questions and provide information about NEXIUM® (esomeprazole magnesium). Fill out the fields below to get started.



Find Representative
AZ GatewayAZ Connect
Close
AZ TouchPoints News
The AZ TouchPoints Web site gives you direct access to AstraZeneca services and support. Here, you can easily find online sample ordering, formulary information, and patient education materials for select AstraZeneca medicines. Go to About AZ TouchPoints
AstraZeneca Professional Sites
To learn more about AstraZeneca medicines, visit the AZ corporate site for a complete list of professional Web sites.
Go to Web site directory
AstraZeneca Medical Affairs
Visit the AstraZeneca medical affairs Web site to get answers to questions about AZ products and medicines.
Go to AZ US Medical Information

NEXIUM® I.V. for Injection

NEXIUM provides a continuum of care from hospital to home. Flexible administration options include

  • NEXIUM I.V. for Injection
  • NEXIUM for Delayed-Release Oral Suspension
  • NEXIUM Delayed-Release Capsules
 

In two studies, NEXIUM I.V. demonstrated acid control


NEXIUM I.V. for excellent acid control

NEXIUM I.V. provided faster and more pronounced acid control than pantoprazole I.V.

  • Greater number of hours with pH > 4 after dosing with NEXIUM I.V. 40 mg vs pantoprazole I.V. 40 mg when both given by 15-minute infusion (11.8 vs 5.6 hours, respectively; P <0.0001)2
  • Greater number of hours with pH > 4 after dosing with NEXIUM I.V. 40 mg given by 15-minute infusion vs pantoprazole I.V. 40 mg when both given by 15-minute bolus (11.8 vs 7.2 hours, respectively; P <0.001)2
  • Data from a randomized, open-label, 3-way crossover study comparing pharmacodynamic parameters in healthy subjects treated with NEXIUM I.V. 40 mg, pantoprazole I.V. 40 mg, both by 15-minute infusion, and pantoprazole I.V. 40 mg given as a 5-minute bolus injection. There was a washout period of at least 14 days between each treatment2
Adapted from Hartmann et al, 2007.

Proven acid control with NEXIUM I.V. vs NEXIUM oral:
impressive mean duration with intragastric pH >4

  • Day 1: 10.1 hours with NEXIUM I.V. 40 mg vs 8.8 hours with NEXIUM oral 40 mg3
  • Day 5: 15.9 hours with NEXIUM I.V. 40 mg vs 15.3 hours with NEXIUM oral 40 mg3
Data from a randomized, double-blind, 2-way crossover study comparing pharmacodynamic parameters in healthy subjects treated for 5 days with at least a 13-day washout period. All infusions administered over a period of 30 minutes.

Adapted from Wilder-Smith et al, 2005.

Educational Resources

Download and print helpful GERD-related resources for your patients.

Get started now

Accessibility of NEXIUM

Search by state to find plan coverage for NEXIUM in your area.

Get started now

Sign Up

Receive updates and offers from the maker of NEXIUM.

Register Now


Approved Uses

NEXIUM I.V. for Injection

NEXIUM I.V. for Injection is indicated for the short-term treatment (up to 10 days) of adult GERD patients with a history of erosive esophagitis (EE) as an alternative to oral therapy when therapy with NEXIUM Delayed-Release Capsules is not possible or appropriate. Treatment with NEXIUM I.V. should be discontinued as soon as the patient is able to continue treatment with NEXIUM Delayed-Release Capsules.

NEXIUM

Treatment of Gastroesophageal Reflux Disease (GERD)

Healing of Erosive Esophagitis (EE)

NEXIUM oral 40 mg and NEXIUM 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed EE.

Maintenance of Healing of EE

NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE. Controlled studies did not extend beyond 6 months.

Symptomatic GERD

NEXIUM 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD.

Pediatric Use

NEXIUM is indicated for the short-term treatment (up to 8 weeks) of GERD (symptomatic GERD and healing of EE) in patients aged 1 to 17 years of age. Pediatric use is supported by extrapolation of results from studies that supported the approval for NEXIUM for adults and safety and pharmacokinetic studies performed in pediatric and adolescent patients.

Effectiveness has not been demonstrated in patients less than 1 year of age. Safety and effectiveness for other pediatric uses have not been established.

Important Safety Information

Please click here for the full Prescribing Information pdf (PDF – 303 KB) for NEXIUM.

Please click here for the full Prescribing Information pdf (PDF – 82 KB) for NEXIUM I.V.

References
  1. Wilder-Smith CH, Rohss K, Bondarov P, et al. Aliment Pharmacol Ther. 2004;20(10):1099-1104.
  2. Hartmann D, Eickhoff A, Damian U, Riemann JF, Schilling D. Eur J Gastroenterol Hepatol. 2007;19(2):133-137.
  3. Data on file, eSTaR #271410.